CV Sciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-958.0K | $-2.4M | $3.1M | $-8.2M | $-15.6M | $-22.3M | $-16.6M | $10.0M |
| Depreciation & Amortization | $192.0K | $334.0K | $235.0K | $992.0K | $1.2M | $872.0K | $716.0K | $519.0K |
| Depreciation | $200.0K | $300.0K | $200.0K | $1.0M | $1.2M | $800.0K | $700.0K | $500.0K |
| Amortization | $24.0K | $21.0K | $1.0K | — | — | — | — | — |
| Stock-Based Compensation | $497.0K | $258.0K | $218.0K | $1.0M | $3.2M | $3.9M | $5.6M | $2.9M |
| Net Cash from Operating Activities | $-407.0K | $-861.0K | $2.3M | $-1.9M | $-7.5M | $-7.3M | $-2.2M | $12.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $109.0K | $18.0K | $0 | $0 | $35.0K | $1.1M | $1.1M | $893.0K |
| Business Acquisitions | $0 | $10.0K | $156.0K | $0 | — | — | — | — |
| Net Cash from Investing Activities | $-109.0K | $-28.0K | $-156.0K | $0 | $-35.0K | $-1.1M | $-1.1M | $-1.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $337.0K | $32.0K | $-1.4M | $1.1M | $4.4M | $3.3M | $47.0K | $-1.2M |
| Net Change in Cash | $-176.0K | $-863.0K | $706.0K | $-764.0K | $-3.2M | $-5.1M | $-3.3M | $10.1M |
| Free Cash Flow | $-516.0K | $-879.0K | $2.3M | $-1.9M | $-7.5M | $-8.4M | $-3.4M | $11.7M |